IngevityFRA:IGX -1.53%65 ROE % is 701.24% as of Mar. 2026, which is 2774% above its 10-year median of 24.40. GuruFocus rates FRA:IGX with a GF Score™ of 65/100 and a GF Value™ of €37.59. The stock has 6 warning signs investors should review. Among 1,591 Chemicals companies, Ingevity ranks worse than 97.74% on this metric.
ROE % is calculated as Net Income divided by its average Total Stockholders Equity over a certain period of time. Ingevity's annualized net income for the quarter that ended in Mar. 2026 was €207 Mil. Ingevity's average Total Stockholders Equity over the quarter that ended in Mar. 2026 was €30 Mil. Therefore, Ingevity's annualized ROE % for the quarter that ended in Mar. 2026 was 701.24%.
The historical rank and industry rank for Ingevity's ROE % or its related term are showing as below:
FRA:IGX'
s ROE % Range Over the Past 10 Years
Min: -148.6 Med: 24.4 Max: 64.72
Current: -113.7
During the past 13 years, Ingevity's highest ROE % was 64.72%. The lowest was -148.60%. And the median was 24.40%.
FRA:IGX's ROE % is ranked worse than 97.74% of 1591
companies
in the Chemicals industry
Industry Median: 5.19
vs FRA:IGX: -113.70
Ingevity (FRA:IGX) ROE % Explanation
ROE % measures the rate of return on the ownership interest (shareholder's equity) of the common stock owners. It measures a firm's efficiency at generating profits from every unit of shareholders' equity (also known as net assets or assets minus liabilities). ROE % shows how well a company uses investment funds to generate earnings growth. ROE %s between 15% and 20% are considered desirable.
The factors that affect a company's ROE % can be illustrated with the three-step DuPont Analysis:
Note:
The net income data used here is four times the quarterly (Mar. 2026) net income data. The Revenue data used here is four times the quarterly (Mar. 2026) revenue data. The same rule applies to Pre-Tax Income and Operating Income.
* In the five-step DuPont Analysis, Operating Income is only available for non-financial companies. Thus, for Insurance companies, we use EBIT as a substitution of Operating Income. For Banks, both Operating Income and EBIT is unavailable. Thus we combined Interest Burden and Operating Margin % into Pretax Margin %, and the DuPont Analysis is divided into four components instead.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Be Aware
Net Income is used.
Because a company can increase its ROE % by having more financial leverage, it is important to watch the equity multiplier when investing in high ROE % companies. Like ROA %, ROE % is calculated with only 12 months data. Fluctuations in company's earnings or business cycles can affect the ratio drastically. It is important to look at the ratio from a long term perspective.
Asset light businesses require very few assets to generate very high earnings. Their ROE %s can be extremely high.
Ingevity ROE % Related Terms
Ingevity ROE % Historical Data
* Premium members only.
The historical data trend for Ingevity's ROE % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Specialty Chemicals subindustry, Ingevity's ROE %, along with its competitors' market caps and ROE % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Ingevity ROE % vs Chemicals Industry
For the Chemicals industry and Basic Materials sector, Ingevity's ROE % distribution charts can be found below:
* The bar in red indicates where Ingevity's ROE % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
In the calculation of annual ROE %, the net income of the last fiscal year and the average total shareholder equity over the fiscal year are used. In calculating the quarterly data,
the net income data used here is four times the quarterly (Mar. 2026) net income data.
ROE % is displayed in the 30-year financial page.
Ingevity (FRA:IGX) has a ROE % of 701.24% as of Mar. 2026. Return on equity is the ratio of current-period net income to average two-period total equity. View historical data on Ingevity and its competitors. This is 2774% above median its historical median of 24.40. According to the industry distribution chart, Ingevity ranks #1555 out of 1591 companies in the Chemicals industry, placing it in the top 97.7%.
Is Ingevity's ROE % too high?
Ingevity's current ROE % of 701.24% is 2774% above median its 10-year median of 24.40. The Chemicals industry median ROE % is 5.19. Ingevity's value of 701.24% is 13411.4% above this industry median. Based on the distribution chart, Ingevity ranks #1555 out of 1591 companies in the Chemicals industry, which is in the bottom quartile relative to peers. Overall, Ingevity has a GF Score™ of 65/100, reflecting its overall financial health beyond just this single metric.
How does Ingevity's ROE % compare to MTX and KWR?
According to the Chemicals industry distribution chart, Ingevity ranks #1555 out of 1591 companies for ROE %. This places Ingevity in the lower half of its industry. The industry median ROE % is 5.19. Ingevity's value of 701.24% is 13411.4% above this benchmark. While the company's 10-year median is 24.40 vs. the industry median of 5.19, Ingevity has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good ROE % for a Chemicals company?
The median ROE % among Chemicals companies is 5.19, based on 1,591 companies in the industry. Companies in the top quartile (top 25%) have a ROE % significantly above this median, while those in the bottom quartile fall well below. However, ROE % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Ingevity's current ROE % of 701.24% is 13411.4% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high ROE % mean?
A high ROE % can signal that a stock is expensive relative to its fundamentals. Return on equity is the ratio of current-period net income to average two-period total equity. View historical data on Ingevity and its competitors. For the Chemicals industry, the median ROE % is 5.19 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Ingevity's current ROE % is 701.24%, which is 2774% above median its own 10-year median of 24.40. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Ingevity stock overvalued right now?
Ingevity (FRA:IGX) has a current ROE % of 701.24%. The stock's GF Value™ is €37.59, compared to a current price of €64.50 — trading 71.6% above its estimated fair value. The current ROE % is 701.24%, which is 2774% above median its 10-year median of 24.40 and 13411.4% above the Chemicals industry median of 5.19. Ingevity's overall GF Score™ is 65/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is ROE % calculated?
ROE % is calculated from a company's financial statements. For Ingevity (FRA:IGX), the current ROE % is 701.24% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Ingevity (FRA:IGX) Overvalued in 2026?
Based on GuruFocus' analysis, Ingevity stock appears to be overvalued.
The current stock price of €64.50 is trading 71.6% above its estimated GF Value™ of €37.59.
Key valuation signals for FRA:IGX:
ROE %: 701.24% (2774% above median its 10-year median of 24.40)
GF Value™: €37.59 vs. price of €64.50 (71.6% above fair value)
Industry Position: 13411.4% above the Chemicals median (#1555 of 1591)
No single metric tells the full story. See the FRA:IGX stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Ingevity Corp is a chemical manufacturer based in the United States. It conducts its operations through three segments, namely Performance Chemicals, Advanced Polymer Technologies, and Performance Materials. The bulk of its revenue is generated by the Performance Chemicals segment which deals with the manufacture and sale of specialty chemicals that find their use in a range of processes such as asphalt paving, oil exploration and production, agrochemicals, adhesives, lubricants, and publication inks. The Performance Materials segment, on the other hand, focuses on automotive carbon products used in automobiles. The Advanced Polymer Technologies segment produces caprolactone and caprolactone-based specialty polymers. The company generates the majority of its revenue from North America.
65GF Score
Get the complete analysis for FRA:IGX
ROE % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
FRA:IGX has been successfully added to your 
